Raven Biotechnologies
South San Francisco · Founded 1999
About Raven Biotechnologies
Raven biotechnologies, Inc., a biotechnology company, focuses on the development of monoclonal antibody therapeutics for treating cancer. Its lead product candidate, RAV12, targets adenocarcinomas and used for the treatment of gastrointestinal, lung, colon, pancreatic, prostate, breast, brain, and ovarian cancer. The company was founded in 1999 and is based in South San Francisco, California. As of July 17, 2008, Raven Biotechnologies, Inc. operates as a subsidiary of MacroGenics, Inc.
Company Facts
- Founded: 1999
- Legal name: Raven Biotechnologies, Inc.
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Total funding: $88.3M
- Funding stage: M&A
- Last round: Series D (Oct 2005)
- Website: macrogenics.com
Social Profiles
Canonical: https://fsome.com/organization/raven-biotechnologies-8260189 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.